17 results about "FOXM1" patented technology

The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN / FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.

The invention relates to the technical field of biological medicine, in particular to a polypeptide self-assembly PROTAC degradation agent and a preparation method and application thereof. The polypeptide self-assembly PROTAC degradation agent comprises a self-assembly group, an E3 ligase recognition group, a cathepsin response group, an FOXM1 targeting binding group, a connecting peptide and an integrin alpha 6 targeting peptide, the amino acid sequence of the FOXM1 targeted binding group is as shown in SEQ ID NO: 1. According to the polypeptide-based nano delivery system, the drug delivery efficiency is remarkably improved, meanwhile, the risk of side effects is reduced to the minimum through controllable release of active fragments, and a basis is provided for preparation of tumor drugs.

A pharmaceutical composition for preventing, ameliorating, or treating cancer, the pharmaceutical composition comprising an FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. The FOXM1 inhibitor inhibits the expression of PD-L1 in a cell membrane and inhibits the translocation of FOXM1 to the nucleus, thereby reducing the proliferation and survival of cancer cells and inducing an increase in cell death, and thus has the effect of preventing, ameliorating, or treating cancer. In addition, when the FOXM1 inhibitor is administered in combination with an immune checkpoint inhibitor, tumor growth is inhibited more effectively than when the FOXM1 inhibitor or immune checkpoint inhibitor is used alone. Thus, the pharmaceutical composition can be useful as an agent for preventing or treating cancer.

The present invention discloses a computer device and computer-readable storage medium for identifying or assisting in the identification of large cell transformation of mycosis fungoides. The present invention provides a computer device comprising a memory, a processor, and a computer program stored in the memory, wherein the processor performs the following steps: S1) data reception: receiving the percentage of FOXM1-positive cells in skin lesions of a subject with mycosis fungoides (MF); S2) data output: outputting result information from the computer based on the percentage of FOXM1-positive cells, wherein the result information indicates whether the subject with mycosis fungoides has, or is a candidate for, large cell transformation of mycosis fungoides. Experiments in the present invention demonstrate that immunohistochemical staining for FOXM1 can more accurately locate large cells and quantify the proportion of large cells compared to traditional pathological techniques, thereby reducing subjective bias. Therefore, it is proposed that immunohistochemical staining for FOXM1 can be used as an auxiliary technique for diagnosing large cell transformation of mycosis fungoides.

The present application relates to a kind of FOXM1 protein phosphorylation modification interfering peptide and its application, belong to the field of biological medicine technology. Specifically, the present application is found in research, the transcriptional activity of FOXM1 protein depends on the condensate formed by its polymerization, destroying the polymerization of FOXM1 can effectively inhibit the occurrence and development of tumor, and the phosphorylation of the 376th amino acid of FOXM1 protein can also inhibit polymerization to some extent, thereby inhibiting the transcriptional activation of FOXM1 protein. Therefore, the present application designs an interfering peptide, and introduces phosphorylation modification in appropriate position, obtains a kind of phosphorylation modification interfering peptide FIP4 targeted to FOXM1 protein polymerization domain, the interfering peptide plays a significant role in inhibiting the transcriptional activation of FOXM1 protein in cell and animal in vivo, and can be used for treating tumor-related diseases.

The invention relates to methods for producing preparations comprising recombinant adeno-associated virus (rAAV) particles. More particularly, the present invention relates to methods comprising a step of contacting a host cell with a polo like kinase (PLK) modulator, a cell cycle modulator preferably an Aurora kinase modulator or a FOXM1 modulator, a microtubule modulator, a histone deacetylase (HDAC) modulator, a G protein-coupled receptor (GPCR) modulator or a JAK modulator.

The present disclosure provides T-cell receptors comprising an antigen binding variable region that specifically binds an antigenic peptide derived from FOXM1. The present disclosure further provides activated or engineered T-cells comprising the T-cell receptors of the disclosure, and methods of making and using these T-cell receptors. Aspects of the disclosure further relate to a polypeptide comprising an antigen binding variable region comprising a CDR3 region of the disclosure.

The present invention relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting growth, migration and invasion of cancer cells. In addition, it relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting malignancy in a tumor microenvironment by inhibiting polarization into tumor-associated macrophages in a tumor microenvironment. It relates to a use as an apoptotic inducer using the action of sensitively inhibiting cancer cell death in metastatic cancer cells as well as general solid cancers.

The invention discloses FFAR1 for inhibiting malignant progression of glioma by reducing expression of MYBL2 regulated by FoxM1, and belongs to the field of targeted gene therapy. The invention finds that the expression of the FFAR1 in the brain tissue of a glioma patient is reduced, which indicates that the FFAR1 has obvious correlation with the glioma and can be used as a biomarker of the glioma. The invention finds that glioma cells overexpressing FFAR1 are inhibited in the aspects of proliferation, migration and invasion, and the cell cycle process is slowed down; and glioma cells for silently expressing the FFAR1 can play a reverse effect, which indicates that the FFAR1 can be used as a treatment target of glioma.

Provided is a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting growth, migration and invasion of cancer cells. In addition, provided is a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting malignancy in a tumor microenvironment by inhibiting polarization into tumor-associated macrophages in a tumor microenvironment. It relates to a use as an apoptotic inducer using the action of sensitively inhibiting cancer cell death in metastatic cancer cells as well as general solid cancers.

A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

The invention discloses a computer device and a computer readable storage medium for identifying or assisting in identifying transformation of mushroom-like granulomegaly cells. The invention provides a computer device, which comprises a memory, a processor and a computer program stored on the memory, and the processor executes the following steps: S1) data receiving: receiving the percentage of FOXM1 positive cells in skin lesion tissues of a mushroom granuloma (MF) subject; and S2) data output: outputting result information from a computer based on the percentage of the FOXM1 positive cells, wherein the result information indicates whether the mushroom-like granuloma subject is or is candidate to be the transformation of the mushroom-like granuloma cells. Experiments prove that compared with a traditional pathological technology, immunohistochemical staining of FOXM1 can more accurately position large cells and quantify the proportion of the large cells, and subjective bias can be reduced. Therefore, the immunohistochemical staining of the FOXM1 can be used as one of auxiliary technologies for diagnosing the transformation of the mushroom-like granulomegaly cells.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer, the pharmaceutical composition comprising an FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. The FOXM1 inhibitor of the present invention inhibits the expression of PD-L1 in a cell membrane and inhibits the translocation of FOXM1 to the nucleus, thereby reducing the proliferation and survival of cancer cells and inducing an increase in cell death, and thus has the effect of preventing, ameliorating, or treating cancer. In addition, when the FOXM1 inhibitor is administered in combination with an immune checkpoint inhibitor, tumor growth is inhibited more effectively than when the FOXM1 inhibitor or immune checkpoint inhibitor is used alone, and thus the pharmaceutical composition according to the present invention can be useful as an agent for preventing or treating cancer.

The present invention provides epitope peptides derived from FOXM1 having the ability to induce cytotoxic T cells. The present invention also provides polynucleotides encoding the peptides, antigen presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods for inducing antigen presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as active ingredients. In addition, the present invention provides methods for treating and / or preventing cancer, and / or preventing its postoperative recurrence using the peptides, polynucleotides, antigen presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. A method for inducing an immune response against cancer is also provided.

The present application relates to the technical field of medicine, in particular to the use of a substance specifically binding to KLK8 in the preparation of a product for the prevention, treatment or diagnosis of sepsis, which treats sepsis by: 1) reducing endothelial cell permeability or improving capillary leakage; 2) stimulating the VE-cadherin / Akt / FOXM1 signaling pathway; preferably, selected from up-regulating the expression level of FOXM1 and its downstream target genes, up-regulating the protein level of AKT or p-AKT, or up-regulating the protein level of VE-cadherin; 3) increasing the proliferation rate of endothelial cells; 4) reducing the mortality rate of endothelial cells; 5) increasing the activity of endothelial cells. The present application provides a new treatment strategy for sepsis complicated with microvascular barrier dysfunction.

This invention discloses a combined application of FOXM1 inhibitor and BUB1 inhibitor, which has significant anti-tumor effects, synergistic effects and low toxicity. It is particularly suitable for the treatment of liver cancer, triple-negative breast cancer and melanoma, and solves the problems of poor efficacy, narrow indications, easy drug resistance and easy recurrence of monotherapy, providing a new strategy for tumor treatment.

The present invention relates to a diagnostic biomarker composition for PARP inhibitor response and a pharmaceutical composition for cancer treatment, including at least one miRNA selected from the group consisting of exosomal miR-664a-5p, miR-98-5p, and miR-95-3p as an active ingredient. The biomarker of the present invention can predict the therapeutic responsiveness and prognosis of cancer patients to PARP inhibitors, enabling the early identification of patients in whom the efficacy of PARP inhibitors is limited due to the development of resistance. Additionally, it has been confirmed that the biomarker of the present invention directly targets FOXM1, a transcription factor involved in chemotherapy resistance, to enhance sensitivity to PARP inhibitors. This finding demonstrates that the differential expression of the biomarker of the present invention plays a crucial role in regulating the efficacy of PARP inhibitors. Furthermore, the biomarker of the present invention can be identified as a potential therapeutic target for PARP inhibitor response in cancer patients.Accordingly, the biomarker of the present invention, either alone or in combination with a PARP inhibitor, can be effectively utilized for the treatment, prevention, and improvement of cancer.